Andrew Left: Exact Sciences Cologuard Test Is Not Worth The Cost

According to Andrew Left, EXACT Sciences Corporation EXAS's Cologuard may be a good test, but it's not worth the full $500-$600 cost. 

Left was responding to a report that UnitedHealth Group Inc UNH had added the company's Cologuard, an alternative to a colonoscopy, to its Coverage Determination Guideline, which could lay to rest questions about the product's efficacy. 

United Health did not respond to a request for comment regarding the guideline change. 

Left told Benzinga the key thing to note in the story of Exact Sciences is what United Health would pay to insure the test. 

The news was first reported on BenzingaPro. 

Left is short Exact Sciences, and has a $20 price target. The stock traded at $34.97 in after hours trading at time of publication.